Skip to content. | Skip to navigation

Personal tools

Home > Medical Center > Department Resources > Clinical Practice Guidelines, Protocols & Pathways > Clinical Practice Guidelines > Pharmacologic Management of Select Ophthalmic Indications (AMD, DME, RVO)

guideline 2.176 : Pharmacologic Management of Select Ophthalmic Indications (AMD, DME, RVO)

In order to promote best practices regarding pharmacologic management of neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) the below guideline identifies preferred and secondary agents to be used to treat patients with these select indications. In addition, this guideline will streamline medication utilization and assist with the reduction of drug expenditures through the use of a less expensive therapeutically equivalent agent when appropriate while still maintaining outstanding patient outcomes. [contact Michelle McCarthy]

File Attachment Downloads

view  |  PDF document icon Pharmacologic-Management-Ophthalmic-Indications-Guideline.pdf — PDF document, 135 KB (138495 bytes)


  1. effective date:

    05/01/2016
nav - root (DO NOT EDIT)